Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 8/20 | 0.48 |
| ▸ | PPARA | Q07869 | 8/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16381756 | 0.98 | CA12 (0.56) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL26372840 | 0.86 | DRD1 (0.41) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL2863928 | 0.84 | SOS1 (0.46) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL6196935 | 0.84 | DRD1 (0.45) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL3798335 | 0.83 | CA12 (0.62) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL2863795 | 0.82 | DRD1 (0.41) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL16381822 | 0.82 | ALDH1A1 (0.54) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL7569927 | 0.81 | NPC1 (0.48) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL30122908 | 0.81 | CA12 (0.66) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL1666926 | 0.81 | DRD1 (0.60) | DRD1DRD2DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114369055-B | Organic compound and organic electroluminescent device comprising same | 武汉尚赛光电科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-3708563-B1 | SELENOPSAMMAPLIN A AND DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, AND COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENTS | SEOUL NAT UNIV R&DB FOUNDATION (KR) | 2024-04-17 | — | — | EP | disclosed |
| US-11629123-B2 | Selenopsammaplin A and derivative thereof, preparation method therefor, and composition for preventing and treating cancer, containing same as active ingredients | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2023-04-18 | — | — | US | disclosed |
| CN-111225875-B | Salt recovery solution and method of using salt recovery solution | 阿克福特斯技术有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-11374176-B2 | Aromatic heterocyclic derivative, material for organic electroluminescent element, and organic electroluminescent element | IDEMITSU KOSAN CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| EP-3902664-A1 | DECORATIVE WALL OR FLOOR COVERING INSTALLATION METHOD | Tarkett GDL (LU) | 2021-11-03 | — | — | EP | disclosed |
| US-20210171458-A1 | SELENOPSAMMAPLIN A AND DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, AND COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENTS | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2021-06-10 | — | — | US | disclosed |
| US-20210101861-A1 | NOVEL REXINOID COMPOUNDS AND METHODS OF USING REXINOID COMPOUNDS FOR TREATING METABOLIC DISORDERS AND CANCER | THE UAB RESEARCH FOUNDATION (US) | 2021-04-08 | — | — | US | disclosed |
| US-10800726-B2 | Rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer | THE UAB RESEARCH FOUNDATION (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3708563-A1 | SELENOPSAMMAPLIN A AND DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, AND COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENTS | Seoul National University R & DB Foundation (KR) | 2020-09-16 | — | — | EP | disclosed |
| WO-2009089001-A2 | DIRECT-TO-METAL RADIATION CURABLE COMPOSITIONS | BAYER MATERIALSCIENCE LLC (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2006085937-A1 | UV CURABLE COATING COMPOSITION | BAYER MATERIALSCIENCE LLC (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1687385-A1 | ULTRAVIOLET-CURABLE POLYOLS AND POLYURETHANE COMPOSITIONS MADE THEREFROM | Bayer MaterialScience LLC (US) | 2006-08-09 | — | — | EP | disclosed |
| CN-1630656-A | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORP (JP) | 2005-06-22 | — | — | CN | disclosed |
| WO-2005049748-A1 | ULTRAVIOLET-CURABLE POLYOLS AND POLYURETHANE COMPOSITIONS MADE THEREFROM | BAYER MATERIALSCIENCE LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1164886-A1 | LOOP FASTENING MATERIAL | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000057742-A1 | LOOP FASTENING MATERIAL | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-1996005962-A1 | RADIATION-CURABLE ORGANOPOLYSILOXANE RELEASE COMPOSITIONS | AVERY DENNISON CORPORATION (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995023694-A1 | RADIATION CURABLE SILICONE RELEASE COMPOSITIONS AND COATED SUBSTRATES | AVERY DENNISON CORPORATION (US) | 1995-09-08 | — | — | WO | disclosed |
| US-4254035-A | BY REACTING GLYCINE AND AN AROMATIC ALDEHYDE IN THE PRESENCE OF ACETIC ANHYDRIDE | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11629123-B2 | Selenopsammaplin A and derivative thereof, preparation method therefor, and composition for preventing and treating cancer, containing same as active ingredients | PSAP, NOTUM, HASPIN | CA12 3827/4885CA1 3946/4885CA2 4778/4885 |
| US-20210171458-A1 | SELENOPSAMMAPLIN A AND DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, AND COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENTS | PSAP, NOTUM, HASPIN | CA12 3827/4885CA1 3946/4885CA2 4778/4885 |
| US-11374176-B2 | Aromatic heterocyclic derivative, material for organic electroluminescent element, and organic electroluminescent element | RER1, L1CAM, ESR1 | CA12 586/4885CA1 1053/4885CA2 2017/4885 |
| US-10800726-B2 | Rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer | GPR119, PNLIP, LIPC | CA12 4640/4885CA1 4852/4885CA2 4735/4885 |
| US-20210101861-A1 | NOVEL REXINOID COMPOUNDS AND METHODS OF USING REXINOID COMPOUNDS FOR TREATING METABOLIC DISORDERS AND CANCER | GPR119, PNLIP, RXRG | CA12 4606/4885CA1 4849/4885CA2 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.